18 F-fluciclovine is a synthetic amino acid radiotracer that has recently been approved in Europe and the United States for PET imaging in men with biochemical recurrence (BCR) of prostate cancer after prior definitive treatment. Accurate identification of the sites of disease in patients presenting with BCR of prostate cancer is important in determining the appropriate treatment. Bone is the most frequent site of metastatic disease in patients with prostate cancer. Methods: We conducted a comprehensive review of the available preclinical and clinical data on the diagnostic performance of 
Most patients who are diagnosed with prostate cancer have clinically localized disease, which may be due to prostate-specific antigen (PSA) screening practice in the United States.
1 Despite curative-intent treatments (eg, radical prostatectomy, external beam radiation therapy), recurrence defined by rising levels of PSA (biochemical recurrence or BCR) occurs in 20% to 40% of patients. [2] [3] [4] This relatively high rate of recurrence after curative-intent treatment may be due to biological factors (eg, aggressiveness of the primary tumor, early dissemination and cellular escape), or inadequate initial staging with standard-of-care imaging methods. Accurate localization of disease sites (eg, local recurrence in the treated prostate bed, distant oligometastatic and polymetastatic disease) has major ramifications on subsequent treatment strategy. Salvage therapy (eg, radiation to treated prostate bed, pelvic nodal dissection) may be an option for limited local recurrence or regional nodal disease, whereas oligometastatic (≤5 lesions) disease may be amenable to lesion-directed therapy (eg, excision, radiation) and polymetastatic disease is treated with systemic therapy (eg, androgen deprivation therapy [ADT], chemotherapy).
Metastases of prostate cancer typically spread first to regional and distant lymph nodes, and ultimately to the skeleton and soft tissue organs. [5] [6] [7] Although bone metastases are initially asymptomatic, they can become painful and result in pathologic fractures or spinal cord compression. 8 Among patients with prostate cancer, but no bone metastases, and rising PSA levels despite ADT, 33% will develop one or more bone metastases within 2 years, with a median bone metastasis-free survival of 32 months. 9 
IMAGING OF BONE METASTASES
The development of BCR represents a critical juncture in the progression of prostate cancer and might be considered the last opportunity for curative therapy. To determine the most appropriate therapy, accurate determination of the extent of disease is essential. Current standard-of-care imaging typically includes bone scintigraphy, contrast-enhanced CT of the chest, abdomen, and pelvis, and, increasingly, the use of multiparametric MRI (mpMRI) of the pelvis. Detection of distant metastatic disease, including bone metastases, precludes potential curative salvage radiotherapy of the prostate bed, although localized treatment (eg, with stereotactic body radiotherapy) may also be considered in patients with oligometastatic bone lesions.
Bone Scintigraphy
Currently, bone scanning (bone scintigraphy, typically with 99m Tc-MDP) is the most widely used method for evaluating bone metastases of prostate cancer and is recommended for staging in those considered to have intermediate-to high-risk disease, and in all patients who are symptomatic. 10, 11 Imaging is facilitated through adsorption of labeled MDP to the hydroxyapatite mineral of bone osteoblasts during normal bone growth and turnover, allowing local bone metabolism to be visualized. 12 Thus, although osteoblastic bone metastases can be detected with relatively high sensitivity, the indirect detection of osteoblastic processes, rather than direct assessment of tumor proliferation, can result in false-positive findings from nonmalignant causes or false-negative outcomes for osteolytic metastases where an osteoclastic process is the biological feature. 13, 14 Suboptimal specificity 15, 16 and limited spatial resolution can also hinder bone lesion localization and characterization.
14 Also associated with bone scanning is the osteoblastic flare, whereby bone regeneration after successful treatment of a bone metastasis can result in visualization of marrow lesions with a sclerotic rim around an initially lytic lesion or sclerosis of lesions that were previously undetected. This lesion healing is sometimes misinterpreted as progressive disease. 13, 17 Given these limitations, a need exists for an imaging method to be used either independently, or in combination with bone scintigraphy, to reliably locate or exclude potential bone metastases in patients with prostate cancer.
MRI
MRI is currently a favored option for the detection of metastases in the bone marrow cavity owing to its excellent soft tissue resolution. 13 Tc-labeled phosphonates, 18 F-NaF PET was available for skeletal imaging, but was of limited clinical utility owing to inadequate accessibility to PET scanners, challenges with radiotracer availability, and the relatively high cost of the procedure. 20, 21 However, several studies have shown that Other metabolic (eg, FDG) or targeted PET radiotracers (eg, agents targeted to prostate-specific membrane antigen) also accumulate in metastatic bone lesions. However, as with choline, more studies are needed to decipher their role in relation to bone scanning and to understand the modulatory effect of various treatments on radiotracer localization in metastatic bone lesions.
F-FLUCICLOVINE

18
F-fluciclovine is a synthetic amino acid PET tracer recently approved in Europe and the United States for use in patients with suspected BCR of prostate cancer for localization of prostatic and extraprostatic lesions. [25] [26] [27] [28] Given the need for a reliable bone imaging method to improve the diagnostic performance of current standardof-care, here we review the evidence to date concerning the detection of metastatic prostate cancer in bone using Tc-hydroxymethylene diphosphonate (HMDP) using tripletracer autoradiography in rat models of osteolytic bone metastases (derived from breast cancer) and osteoblastic bone metastases (derived from prostate cancer). Histological verification confirmed that 14 C-fluciclovine accumulated in areas of metastatic invasion in both the osteoclastic and the osteoblastic models. The distribution patterns of Of note, fluciclovine, in contrast to 99m Tc-HMDP, did not accumulate in areas of new bone formation after bone damage, suggesting a reduced potential for false-positive findings due to nonmalignant bone disease, a known confounder in patients undergoing bone scanning. The authors concluded that fluciclovine PET can visualize true osteolytic and osteoblastic bone metastases, suggesting it could be useful in the detection of bone metastases from many types of cancer, including breast and prostate cancer.
A further study from the same group investigated the impact of fasting before fluciclovine-PET using triple-tracer autoradiography with 14 C-fluciclovine, 3 H-FDG, and 99m Tc-HMDP in a rat Tc-MDP bone scans performed within 28 days preceding the 18 F-fluciclovine PET/CT scan. In total, 68 patients with biopsy-proven prostate cancer scheduled either to undergo radical prostatectomy and extended lymphadenectomy (n = 44) or to be treated with ADT (n = 24) because of the presence of metastases, were enrolled. A total of 14 bone metastases were identified by bone scan/contrast-enhanced CT. After the administration of 18 F-fluciclovine, PET/CT images were acquired within 30 minutes, yielding a positive predictive value (PPV), negative predictive value (NPV), sensitivity, and specificity of 0.61, 0.92, 0.73, and 0.86, respectively, for detection of bone metastases. 31, 32 Bone metastases were evaluated by comparative diagnosis using integrated findings of bone scintigraphy and whole-body contrast-enhanced CT; the concordance rate for diagnosis of bone metastasis by 18 F-fluciclovine PET/CT and that based on the combined conventional imaging in the 66 patients who were evaluated for bone metastases was 0.83 (95% CI, 0.72-0.91) with an associated κ coefficient of 0.557 (95% CI, 0.326-0.788) that suggested moderate concordance. 18 F-fluciclovine PET/CT identified 7 cases of bone metastases that were not identified by either bone scintigraphy or whole-body CT, probably because of the ability to visualize early marrow involvement with 18 F-fluciclovine. Four cases were deemed positive based on whole-body contrast-enhanced CT findings, but were negative according to the 18 F-fluciclovine PET/CT. The authors attributed this discordance to benign bone islands and not metastases.
A large, multicenter, retrospective study (BED001, NCT02443571) reported efficacy and safety data from 596 patients who underwent a total of 610 18 F-fluciclovine scans for suspected BCR of prostate cancer. 25 Data from this study, initially presented at American Society for Radiation Oncology (ASTRO) 2016, revealed a low detection rate (9%) for bone metastases across all participating centers with 18 F-fluciclovine PET/CT. 33, 34 Data from BED001 that compared 18 F-fluciclovine PET/CT with other imaging methods are presented in Table 1. 34 These include bone SPECT findings from one site (Emory University), which required all patients to have had a negative planar bone scan before 18 F-fluciclovine PET/CT. 18 F-fluciclovine PET/CT identified bone lesions in 2 patients, which were missed by conventional bone SPECT imaging. The first patient had multiple areas of uptake in the bony pelvis and the second had uptake in the femur and several lumbar vertebrae within 40 and 30 days, respectively, of a negative bone SPECT. 34 Two other patients had positive bone SPECT after a negative 18 F-fluciclovine PET/CT; one had a suspected lesion in L5 vertebra within the month after the negative 18 F-fluciclovine PET/CT, whereas the other had a positive bone SPECT (10th rib) within 2 months. The investigators suggested that in the latter case the rib was not visible on 18 F-fluciclovine PET/CT, because their image capture protocol limited the field of view to the abdominopelvic region that excluded the area of rib involvement.
Five (71%) of 7 patients from the various centers who had a positive planar bone scan also showed a positive result with 18 F-fluciclovine PET/CT, as did 3/4 (75%) patients with bone lesions detected on MRI and 4/4 patients (100%) with lesions visible on contrast-enhanced CT. Similar high concordance was demonstrated between scan methods with respect to negative findings. When compared with MRI findings as a standard of truth, the PPV, NPV, sensitivity, and specificity of C-choline PET/CT, but eventually positive on follow-up. Among this population, the PPV for bone lesions was shown to be higher for 18 F-fluciclovine (1.00) than for 11 C-choline (0.83). 27 Three illustrative clinical cases are shown in Figures 1 to 3 .
Ongoing Trials-FALCON (NCT02578940) and LOCATE (NCT02680041)
Two open-label multisite studies are currently underway to establish the impact of 18 F-fluciclovine PET/CT on the management of patients with BCR of prostate cancer after primary treatment. FALCON (NCT02578940) is based in the United Kingdom and recently terminated recruitment early owing to overwhelming efficacy. 35, 36 Interim data from FALCON show the 18 F-fluciclovine detection rate for bone lesions in patients with BCR of prostate cancer to be 9/85 (11%).
35 LOCATE (NCT02680041), a similar trial based in the United States, shows a similar bone lesion detection rate of 23/213 (11%). 34 It is noteworthy that all subjects in LO-CATE were required to have a negative bone scan or 18 F-NaF PET/CT before their enrolment. Based on the relatively limited data available at this time, it is reasonable to conclude that 18 F-fluciclovine PET/CT can detect areas of early metastatic disease in bone and might offer complementary localization of bone metastases in patients with prostate cancer when used with standard bone-specific imaging modalities. In cases of negative 18 F-fluciclovine findings and continuing clinical suspicion of bone involvement, additional imaging may be warranted.
